Baseline characteristics, number of participants, n (% of total)* | Total vaccines received by end of follow-up, number of participants, n (% of category)* | |||||
ChAdOx1 | BNT162b2 | Other† | ||||
One dose only | Two doses | One dose only | Two doses | Any doses | ||
Overall | 11 475 (100) | 331 (2.9) | 5497 (47.9) | 270 (2.4) | 4240 (36.9) | 1137 (9.9) |
Sex | ||||||
Male | 4609 (40.2) | 135 (2.9) | 2351 (51.0) | 94 (2.0) | 1574 (34.2) | 455 (9.9) |
Female | 6855 (59.7) | 196 (2.9) | 3141 (45.8) | 176 (2.6) | 2661 (38.8) | 681 (9.9) |
Age (years) | ||||||
18–39 | 1788 (15.6) | 18 (1.0) | 280 (15.7) | 107 (6.0) | 1109 (62.0) | 274 (15.3) |
4–-64 | 4661 (40.6) | 176 (3.8) | 2811 (60.3) | 68 (1.5) | 1170 (25.1) | 436 (9.4) |
65+ | 5023 (43.8) | 137 (2.7) | 2406 (47.9) | 95 (1.9) | 1959 (39) | 426 (8.5) |
BMI (kg/m2) | ||||||
<18.5 | 163 (1.4) | 5 (3.1) | 82 (50.3) | <5 | 61 (37.4) | 13 (8.0) |
18.5–<25 | 3780 (32.9) | 84 (2.2) | 1795 (47.5) | 96 (2.5) | 1492 (39.5) | 313 (8.3) |
25–<30 | 3728 (32.5) | 83 (2.2) | 1906 (51.1) | 71 (1.9) | 1352 (36.3) | 316 (8.5) |
30–<40 | 2441 (21.3) | 75 (3.1) | 1155 (47.3) | 57 (2.3) | 914 (37.4) | 240 (9.8) |
40+ | 518 (4.5) | 14 (2.7) | 260 (50.2) | 10 (1.9) | 197 (38.0) | 37 (7.1) |
Ethnicity | ||||||
Other | 275 (2.4) | 13 (4.7) | 103 (37.5) | 11 (4.0) | 120 (43.6) | 28 (10.2) |
White | 11 200 (97.6) | 318 (2.8) | 5394 (48.2) | 259 (2.3) | 4120 (36.8) | 1109 (9.9) |
Occupational status | ||||||
Unemployed | 524 (4.6) | 20 (3.8) | 214 (40.8) | 18 (3.4) | 203 (38.7) | 69 (13.2) |
Employed | 5053 (44.0) | 146 (2.9) | 2103 (41.6) | 159 (3.1) | 2038 (40.3) | 607 (12.0) |
Retired | 5898 (51.4) | 165 (2.8) | 3180 (53.9) | 93 (1.6) | 1999 (33.9) | 461 (7.8) |
Currently smoke | ||||||
No | 10 189 (88.8) | 245 (2.4) | 4999 (49.1) | 223 (2.2) | 3844 (37.7) | 878 (8.6) |
Yes | 441 (3.8) | 16 (3.6) | 199 (45.1) | 13 (2.9) | 172 (39.0) | 41 (9.3) |
No. of comorbidities | ||||||
None | 3548 (30.9) | 133 (3.7) | 1496 (42.2) | 126 (3.6) | 1312 (37.0) | 481 (13.6) |
1 | 2867 (25.0) | 67 (2.3) | 1463 (51.0) | 56 (2.0) | 1057 (36.9) | 224 (7.8) |
2 | 2253 (19.6) | 58 (2.6) | 1109 (49.2) | 36 (1.6) | 856 (38.0) | 194 (8.6) |
3+ | 2807 (24.5) | 73 (2.6) | 1429 (50.9) | 52 (1.9) | 1015 (36.2) | 238 (8.5) |
Advised to shield | ||||||
Yes | 960 (8.4) | 32 (3.3) | 506 (52.7) | 21 (2.2) | 293 (30.5) | 108 (11.2) |
No | 9600 (83.7) | 225 (2.3) | 4660 (48.5) | 213 (2.2) | 3702 (38.6) | 800 (8.3) |
Had COVID before study entry | ||||||
Yes | 1256 (10.9) | 40 (3.2) | 544 (43.3) | 33 (2.6) | 504 (40.1) | 135 (10.7) |
No | 9304 (81.1) | 217 (2.3) | 4622 (49.7) | 201 (2.2) | 3491 (37.5) | 773 (8.3) |
*Subgroups may not sum to the total because unknowns are omitted.
†Includes participants who received both ChAdOx1 and BNT162b2 and any who reported other COVID-19 vaccines alone or in combination with ChAdOx1 or BNT162b2.
BMI, body mass index.